Plant ID: NPO5986
Plant Latin Name: Ziziphus jujuba
Taxonomy Genus: Ziziphus
Taxonomy Family: Rhamnaceae
NCBI TaxonomyDB:
326968
Plant-of-the-World-Online:
719213-1
Anodyne; Antidote; Astringent; Cancer; Diuretic; Emollient; Expectorant; Hypnotic; Narcotic; Pectoral; Poultice; Refrigerant; Sedative; Skin; Stomachic; Tonic
Turkey; Italy; India; France; Cameroon; Burkina Faso; Algeria; Cuba; Venezuela; Jordan; China; Dominican Republic; Spain; Maldives; Libya; Philippines; United States; Morocco; Thailand; Bulgaria; Jamaica; Romania; Honduras; South Africa; Lebanon; Greece; South Korea
FFAR1; ADORA3; ADORA2A; FFAR4; ADORA1; ADRA2B; DRD3; DRD1; HCAR2; GPR35; DRD5; | |
TSHR; NPSR1; | |
CDC25B; | |
ALPL; RECQL; TDP1; CDA; BLM; ADK; TK1; NOX4; HPGD; HSD11B1; AKR1B10; ALOX12; AKR1B1; HSD17B10; ALOX15; APEX1; POLB; | |
ACHE; | |
TEK; MET; INSR; NUAK1; CDK1; MAPK1; EGFR; PIM1; AXL; FLT3; SRC; KDR; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA9; CA14; CA7; CA4; | |
PPARA; | |
ESR1; ESR2; | |
THRB; | |
RORC; | |
NR1H4; | |
KDM4E; | |
MMP9; MMP1; MMP2; | |
NFKB1; | |
FUT7; | |
KMT2A; | |
SLC22A6; SLCO1B1; | |
SMAD3; LMNA; FABP5; FABP3; F3; FABP4; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | DRD5 | Dopamine D5 receptor | P21918 | CHEMBL1850 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | Unclassified; | GO:0004872; receptor activity | 6.250E-13 | 4.537E-10 | ADORA1, ADORA2A, ADORA3, ADRA2B, AXL, DRD1, DRD3, DRD5, EGFR, ESR1, ESR2, F3, FFAR1, FFAR4, FLT3, GPR35, HCAR2, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK, THRB, TSHR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.733E-11 | 8.984E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.785E-10 | 1.288E-07 | BLM, CA12, CA2, CA4, CA7, CA9, CDA, ESR1, ESR2, KMT2A, MMP1, MMP2, MMP9, NR1H4, PPARA, RORC, SMAD3, THRB, TK1 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.840E-09 | 9.394E-07 | ADORA1, CA2, CA4, CA9, EGFR, HPGD, SLC22A6, SLCO1B1, TEK, TSHR |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.046E-08 | 4.202E-06 | ADORA1, ADORA2A, FFAR4, NFKB1, NR1H4, PPARA, SMAD3, TEK |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.227E-08 | 4.491E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.111E-07 | 1.779E-05 | ADORA1, ADORA2A, ADORA3, ADRA2B, AXL, DRD1, DRD3, DRD5, FFAR1, FFAR4, FLT3, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, SLCO1B1, TEK, TSHR |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.571E-07 | 2.359E-05 | ADORA1, ADORA2A, CA2, CA7, DRD1, DRD3, KDR, NPSR1, SRC |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.798E-07 | 2.646E-05 | AXL, EGFR, F3, INSR, MET, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.223E-07 | 4.413E-05 | CA12, CA2, CA4, CA7, CA9 |
BP | GO:0023052; signaling | GO:0001963; synaptic transmission, dopaminergic | 3.246E-07 | 4.418E-05 | ADORA2A, DRD1, DRD3, DRD5 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.284E-07 | 6.575E-05 | ESR1, ESR2, NR1H4, PIM1, PPARA, RORC, SRC, THRB |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 9.444E-07 | 1.118E-04 | ESR1, ESR2, NR1H4, PPARA, RORC, SRC, THRB |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 9.927E-07 | 1.156E-04 | ADORA1, CYP1A1, LMNA, MMP2, NOX4, PPARA, SMAD3, SRC, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.103E-06 | 1.271E-04 | ADK, AURKB, AXL, BLM, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MAPK1, MET, NUAK1, PIM1, RECQL, SRC, TEK, TK1 |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.163E-06 | 1.313E-04 | ADORA1, ADRA2B, CDK1, EGFR, FLT3, INSR, MAPK1, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.267E-06 | 1.409E-04 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.191E-06 | 2.294E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 3.438E-06 | 3.312E-04 | ADORA2A, DRD1, DRD3, DRD5 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.784E-06 | 3.614E-04 | CDK1, ESR1, ESR2, NR1H4, PPARA, RORC, THRB |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.023E-06 | 3.809E-04 | FABP3, FABP4, FABP5, FFAR4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.701E-06 | 4.374E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.023E-06 | 4.596E-04 | ACHE, ADORA2A, BLM, CDA, CSNK2A1, EGFR, ESR1, ESR2, FLT3, HPGD, IGF1R, KDR, KMT2A, MAPK1, MET, MMP9, NFKB1, SLC22A6, SMAD3, TK1 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 5.229E-06 | 4.744E-04 | ADORA1, ADORA2A, ADORA3 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 5.229E-06 | 4.744E-04 | EGFR, INSR, KDR |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 6.728E-06 | 5.860E-04 | ALOX15, ALPL, EGFR, MMP2, MMP9, TEK |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.919E-06 | 6.002E-04 | AKR1B1, AKR1B10, CYP1A1, CYP1B1, CYP2D6, ESR1, HSD11B1, NR1H4 |
BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 7.448E-06 | 6.360E-04 | DRD1, DRD3, DRD5 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 8.353E-06 | 6.942E-04 | ACHE, ADORA1, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, MMP9, PIM1, PPARA, SMAD3, SRC, TSHR |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 8.525E-06 | 7.058E-04 | ACHE, ADK, AKR1B1, AKR1B10, CYP1A1, CYP1B1, CYP2D6, DRD1, DRD3, EGFR, HSPA1A |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.091E-05 | 8.640E-04 | ADORA1, ADORA2A, ADRA2B, DRD1, DRD5, EGFR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.392E-05 | 1.058E-03 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 1.468E-05 | 1.110E-03 | ADORA3, DRD1, DRD5, TSHR |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.478E-05 | 1.114E-03 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.484E-05 | 1.115E-03 | ALOX15, DRD5, EGFR, PPARA, SMAD3 |
BP | GO:0007610; behavior | GO:0046960; sensitization | 1.610E-05 | 1.168E-03 | DRD1, DRD5 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.610E-05 | 1.168E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.610E-05 | 1.168E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 1.610E-05 | 1.168E-03 | CDA, MAPK1 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.610E-05 | 1.168E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.610E-05 | 1.168E-03 | ALOX12, ALOX15 |
MF | Unclassified; | GO:0032403; protein complex binding | 1.636E-05 | 1.176E-03 | ACHE, ADORA1, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP9, PPARA, SMAD3, SRC, TSHR |
BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.760E-05 | 1.252E-03 | ADORA2A, DRD1, DRD3 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.760E-05 | 1.252E-03 | ADORA2A, CA2, CA7 |
MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.760E-05 | 1.252E-03 | DRD1, DRD3, DRD5 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 2.403E-05 | 1.646E-03 | ACHE, EGFR, IGF1R, INSR, THRB |
BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 2.451E-05 | 1.668E-03 | ADORA1, DRD3, DRD5, PPARA |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 2.555E-05 | 1.726E-03 | APEX1, CDC25B, CDK1, CYP1A1, DRD3, INSR |
BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 2.870E-05 | 1.917E-03 | ACHE, CDA, HSD17B10, IGF1R, INSR, TK1 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 3.012E-05 | 1.982E-03 | ADK, AKR1B1, APEX1, AURKB, BLM, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, FABP5, HPGD, HSPA1A, KMT2A, LMNA, MAPK1, NFKB1, NR1H4, NUAK1, PIM1, POLB, PPARA, RECQL, RORC, SMAD3, SRC, THRB |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.232E-05 | 2.101E-03 | CYP1A1, CYP1B1, CYP2D6, NOX4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.415E-05 | 2.207E-03 | ALOX12, ALOX15, HPGD |
BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 3.728E-05 | 2.394E-03 | ADORA1, ADORA2A, DRD1, DRD5, KMT2A, MAPK1 |
BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 4.547E-05 | 2.791E-03 | EGFR, FLT3, KDR, MAPK1, TEK |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 4.576E-05 | 2.791E-03 | ACHE, ADORA2A, EGFR, FFAR1, HCAR2, NR1H4, SRC |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.817E-05 | 2.874E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.817E-05 | 2.874E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.817E-05 | 2.874E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 4.817E-05 | 2.874E-03 | ADORA1, ADORA2A |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.796E-05 | 3.419E-03 | AKR1B1, AKR1B10, ALOX12, ALOX15, APEX1, CYP1A1, CYP1B1, CYP2D6, HPGD, HSD11B1, HSD17B10, KDM4E, NOX4 |
BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 5.859E-05 | 3.419E-03 | ADORA1, ADORA2A, DRD3 |
MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 6.644E-05 | 3.825E-03 | ADORA1, CDK1, CSNK2A1, HSPA1A, KDR |
BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 7.176E-05 | 4.027E-03 | DRD3, KMT2A, PPARA, RORC |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 7.176E-05 | 4.027E-03 | CDK1, EGFR, IGF1R, INSR |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 9.230E-05 | 5.025E-03 | HPGD, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 9.230E-05 | 5.025E-03 | ESR1, ESR2, SRC |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 9.460E-05 | 5.086E-03 | APEX1, CYP1A1, CYP2D6, KDM4E |
MF | GO:0060089; molecular transducer activity | GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs | 9.608E-05 | 5.128E-03 | DRD1, DRD5 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 9.608E-05 | 5.128E-03 | ESR1, ESR2 |
BP | GO:0051179; localization | GO:0006909; phagocytosis | 1.010E-04 | 5.354E-03 | ADORA1, ADORA2A, ALOX15, AXL |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.058E-04 | 5.567E-03 | CYP1A1, CYP1B1, CYP2D6 |
BP | Unclassified; | GO:0006461; protein complex assembly | 1.086E-04 | 5.682E-03 | ACHE, BLM, CDA, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, KMT2A, SLC22A6, SMAD3, SRC, TEK, TK1 |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.203E-04 | 6.147E-03 | AKR1B1, AKR1B10, HPGD, HSD11B1, HSD17B10 |
BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 1.301E-04 | 6.556E-03 | ACHE, ADORA1, DRD1, DRD5 |
BP | GO:0008152; metabolic process | GO:2000573; positive regulation of DNA biosynthetic process | 1.301E-04 | 6.556E-03 | AURKB, MAPK1, NOX4, SRC |
BP | GO:0050896; response to stimulus | GO:0050927; positive regulation of positive chemotaxis | 1.367E-04 | 6.794E-03 | F3, KDR, SMAD3 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.367E-04 | 6.794E-03 | FABP3, FABP4, FABP5 |
BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 1.377E-04 | 6.829E-03 | ALOX15, HSPA1A, MET, NOX4, SMAD3, TEK |
BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 1.416E-04 | 6.991E-03 | BLM, DRD3, EGFR, ESR1, ESR2, INSR, KMT2A, MAPK1, MET, NFKB1, NR1H4, PPARA, RORC, SMAD3, SRC, THRB |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.431E-04 | 7.019E-03 | CA2, CA9, EGFR, ESR1, MET, SMAD3, SRC |
BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 1.516E-04 | 7.383E-03 | KDR, MET, MMP9, SRC, TEK |
BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 1.516E-04 | 7.383E-03 | ADORA2A, EGFR, FFAR1, HCAR2, NR1H4 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.597E-04 | 7.561E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.597E-04 | 7.561E-03 | BLM, RECQL |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.694E-04 | 7.897E-03 | CYP1A1, CYP1B1, CYP2D6, NOX4, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.821E-04 | 8.365E-03 | EGFR, IGF1R, INSR, KDR, TEK |
CC | GO:0016020; membrane | GO:0005901; caveola | 1.947E-04 | 8.796E-03 | INSR, MAPK1, SLC22A6, SRC |
BP | GO:0051179; localization | GO:0015718; monocarboxylic acid transport | 1.955E-04 | 8.816E-03 | DRD3, FABP3, NR1H4, PPARA, SLCO1B1 |
BP | GO:0023052; signaling | GO:0007267; cell-cell signaling | 2.085E-04 | 9.359E-03 | ADORA1, ADORA2A, ADRA2B, DRD1, DRD3, DRD5, ESR2, MAPK1, TEK, TSHR |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.146E-04 | 9.536E-03 | AXL, IGF1R, INSR |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.168E-04 | 9.594E-03 | CA2, ESR1, MAPK1, TEK |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.537E-10 | 3.993E-08 | SMAD3, CSNK2A1, SRC, INSR, MAPK1, MET, EGFR, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.459E-11 | 6.088E-09 | CA12, CA2, CA4, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.767E-09 | 2.797E-07 | SRC, MMP2, MAPK1, ESR1, MMP9, EGFR, ESR2, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.167E-08 | 5.135E-07 | MMP1, SRC, MMP2, MAPK1, MMP9, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.536E-08 | 2.797E-06 | SRC, MMP2, KDR, MAPK1, ESR1, MMP9, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.042E-08 | 2.797E-06 | HCAR2, ADORA2A, ADORA1, MAPK1, DRD1, PPARA, NFKB1, TSHR, DRD5 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.326E-07 | 2.918E-06 | ADORA2A, SRC, INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.213E-07 | 2.918E-06 | THRB, ADORA2A, GPR35, ADORA3, ADORA1, DRD1, ADRA2B, DRD3, TSHR, DRD5 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.733E-06 | 4.706E-05 | SMAD3, MMP2, PIM1, MAPK1, F3, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.209E-06 | 4.706E-05 | SMAD3, FLT3, MMP1, MMP2, MAPK1, MET, MMP9, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.883E-06 | 4.706E-05 | INSR, KDR, MAPK1, TEK, MET, EGFR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.064E-06 | 4.706E-05 | INSR, MAPK1, TEK, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.563E-06 | 8.885E-05 | HPGD, KMT2A, FLT3, MMP9, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.039E-06 | 1.061E-04 | SRC, MAPK1, ESR1, NFKB1, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.050E-05 | 2.255E-04 | PIM1, CYP1B1, MAPK1, MMP9, MET, EGFR, NFKB1, CDC25B |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 5.464E-05 | 5.062E-04 | INSR, KDR, MAPK1, TEK, MET, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 7.327E-06 | 9.210E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 6.800E-05 | 5.699E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.411E-05 | 2.496E-04 | SRC, CDK1, MAPK1, DRD1, EGFR |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.302E-05 | 4.206E-04 | INSR, CYP1A1, CYP1B1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.383E-04 | 9.737E-04 | SRC, KDR, MAPK1, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.740E-05 | 5.699E-04 | FABP4, INSR, ADORA1, TSHR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.227E-05 | 5.782E-04 | FLT3, PIM1, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.284E-04 | 9.737E-04 | SMAD3, MAPK1, EGFR, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.726E-04 | 1.085E-03 | SMAD3, INSR, MAPK1, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.663E-04 | 1.562E-03 | SMAD3, SRC, MAPK1, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.362E-04 | 9.737E-04 | FLT3, MAPK1, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.706E-04 | 1.085E-03 | MAPK1, MET, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.442E-04 | 9.764E-04 | SRC, MET, EGFR, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 4.936E-04 | 2.633E-03 | ADORA3, INSR, ADORA1, MAPK1, ADRA2B |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 4.065E-04 | 2.308E-03 | MAPK1, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 4.424E-04 | 2.433E-03 | SRC, MMP2, MAPK1, EGFR |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.900E-04 | 1.153E-03 | HSD11B1, CYP2D6, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 5.857E-04 | 3.032E-03 | CDK1, MAPK1, CDC25B, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.241E-03 | 5.783E-03 | POLB, SRC, CDK1, MAPK1, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.665E-04 | 4.860E-03 | CYP2D6, ALOX15, MAPK1, ALOX12 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.173E-03 | 5.736E-03 | THRB, SRC, MAPK1, ESR1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.249E-03 | 5.783E-03 | ADORA3, ADORA1, MAPK1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.823E-03 | 7.824E-03 | MAPK1, PPARA, EGFR, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.745E-03 | 7.680E-03 | SRC, KDR, MAPK1 |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.004E-03 | 8.193E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.095E-03 | 8.193E-03 | MAPK1, EGFR, IGF1R |
09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 2.095E-03 | 8.193E-03 | SMAD3, RORC, NFKB1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.509E-03 | 6.810E-03 | HSD11B1, CYP1A1, CYP1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 2.095E-03 | 8.193E-03 | SRC, MAPK1, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR; FFAR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; ADORA1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; AKR1B1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; HCAR2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; HCAR2; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; THRB; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD5; DRD1; DRD3; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
NA: NA | Edema | NA | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TK1; |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MMP1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; ADORA1; INSR; THRB; HCAR2; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; ADORA1; INSR; AKR1B1; FFAR1; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; TK1; ACHE; ADORA3; TEK; MMP9; MAPK1; EGFR; SRC; MMP2; CDC25B; CA9; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ADORA1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TK1; DRD5; TEK; MMP9; MAPK1; EGFR; CDA; SRC; MMP2; CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HCAR2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; DRD1; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; ADRA2B; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; INSR; EGFR; CA9; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TK1; EGFR; SRC; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; ADORA2A; DRD1; INSR; ADK; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; DRD1; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD3; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; TK1; EGFR; MMP2; F3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; DRD1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; TEK; SRC; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; DRD1; INSR; HCAR2; FFAR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; TK1; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |